The present invention relates to compounds of formula I
wherein
R
1
,
R
2
, and are defined in the specification and to pharmaceutically acceptable acid addition salts thereof.
本发明涉及式I的化合物
其中
R
1
,
R
2
,并在规范中定义,并且其药学上可接受的酸盐。
[EN] MULTIPLE KINASE PATHWAY INHIBITORS<br/>[FR] INHIBITEURS DE MULTIPLES VOIES DE KINASES
申请人:MANNKIND CORP
公开号:WO2014052365A1
公开(公告)日:2014-04-03
Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.
对多种信号通路中的激酶具有抑制活性的激酶及其治疗用途。
Substituted phenyl methanone derivatives
申请人:Jolidon Synese
公开号:US20060160788A1
公开(公告)日:2006-07-20
The present invention relates to compounds of formula I
wherein
R
1
, R
2
, R
3
, n, and m, are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. These compounds are good inhibitors of the glycine transporter 1 (GlyT-1) and are useful for the treatment of CNS disorders such as schizophrenia, cognitive impairment, and Alzheimer's disease.
The present invention relates to compounds of general formula IA or IB
wherein
X
1
and X
2
are each independently N or C—R″ and
R
1
, R
2
,R
3
, R
4
,
R
5
, and R
6
are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The compounds can be used for the treatment of diseases related to the glycine transporter inhibitor, such as schizophrenia and Alzheimer's disease.
The present invention relates to compounds of formula I
wherein
R
1
,
R
2
, X
1
, and X
2
are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. Such compounds are inhibitors of the glycine transporter 1 (GlyT-1) and can be used in the treatment of schizophrenia, cognitive impairment, and Alzheimer's disease.